Identifying the antinociceptive efficacy of vesencumab highlights an opportunity to repurpose a biologic developed for cancer for the treatment of chronic pain, facilitating the development of a nonopioid therapeutic targeting NGF signaling through its coreceptor identified in this study. This evidence concerns the gene NGF and cancer.